3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Burkitt Lymphoma
5
Prostatic Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Biphenotypic, Acute
2
Hematologic Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostate Cancer Recurrent
1
Philadelphia Chromosome
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Interventions
Specimen Handling
5
Magnetic Resonance Spectroscopy
5
Cisplatin
4
trastuzumab deruxtecan
3
Platinum
3
Docetaxel
3
Carboplatin
3
Biopsy
3
pembrolizumab
2
entrectinib
2
darolutamide
2
Trastuzumab
2
Radiotherapy, Intensity-Modulated
2
Leuprolide
2
Goserelin
2
Ado-Trastuzumab Emtansine
2
1,2-diaminocyclohexaneplatinum II citrate
2
zanidatamab
1
trastuzumab biosimilar HLX02
1
sacituzumab govitecan
1
pyrotinib
1
pertuzumab
1
luprolide acetate gel depot
1
larotrectinib
1
enfortumab vedotin
1
dehydroftorafur
1
ceralasertib
1
camrelizumab
1
bicalutamide
1
apatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
Dasatinib
×
90 days
×
Clear all
No trials found.